ArticleF&S reports2024
A comparison of letrozole regimens for ovulation induction in women with polycystic ovary syndrome.
Article in F&S reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07759518 (Letrozole High Dose), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Letrozole High Dose (10 mg) Compared to Letrozole Low Dose( 5 mg) for Ovarian Stimulation in Infertile Women With Polycystic Ovary Syndrome
Who cites it
5 citing papers in PubMed.
- Extended Letrozole Treatment for Ovulation Induction and Clinical Pregnancy in Conventional Treatment-resistant Polycystic Ovary Syndrome Patients: A Prospective Parallel Randomized Clinical Trial.Journal of obstetrics and gynaecology of India · 2025Article
- Hyperandrogenism in polycystic ovary syndrome augments Estrogen synthesis through AR-FOXL2-mediated activation of the aromatase gene in granulosa cells.Journal of ovarian research · 2025Article
- Extending letrozole dosing in patients with polycystic ovary syndrome undergoing ovulation induction with intrauterine insemination.F&S reports · 2025Article
- Letrozole at the Crossroads of Efficacy and Fetal Safety in Ovulation Induction: A Narrative Review.Biomedicines · 2025Review
- Efficacy of an Extended 10-day Letrozole Regimen Compared to the 5-day Regimen in Enhancing Ovulation in Infertile Women with Polycystic Ovary Syndrome: A Randomised Controlled Trial.Journal of human reproductive sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the optimal letrozole regimen for ovulation induction (OI) in women with polycystic ovary syndrome (PCOS). Design: Retrospective cohort study. Setting: Single academic fertility clinic from 2015-2022. Patients: A total of 189 OI cycles in 52 patients with PCOS. Interventions: Patients were prescribed 1 of 4 letrozole regimens (group 1: 2.5 mg for 5 days, group 2: 2.5 mg for 10 days, group 3: 5 mg for 5 days, and group 4: 5 mg for 10 days). Main outcome measures: The primary outcome was ovulation, and secondary outcomes included multifollicular development, and clinical pregnancy rate, which were analyzed with binary logistic regression. Kaplan-Meier cumulative response curves and a Cox proportional hazard regression model were used for time-dependent analyses. Results: Mean age was 30.9 years (standard deviation [SD], 3.6) and body mass index was 32.1 kg/m Conclusions: Ovulation rates are improved when starting with letrozole at 5 mg and/or a 10-day extended course as compared with the frequently-used 2.5 mg for 5 days. This may shorten time to ovulation and pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.